Novocure Ltd. (NVCR)

77.81
1.10 1.40
NASDAQ : Health Technology
Prev Close 78.90
Open 78.49
Day Low/High 76.11 / 78.64
52 Wk Low/High 28.83 / 98.70
Volume 1.19M
Avg Volume 726.00K
Exchange NASDAQ
Shares Outstanding 98.97M
Market Cap 8.05B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Novocure's Charts Are as Bullish As They Get, So Here's My Strategy

Novocure's Charts Are as Bullish As They Get, So Here's My Strategy

The oncology company has had a strong run and all the technical signals indicate the move higher isn't over.

NovoCure Looks Due for a Technical Correction

NovoCure Looks Due for a Technical Correction

Let's look at the charts and indicators in addition to following the fundamentals.

Upgrades, Downgrades, Initiations

Here we go folks, a sampling of this morning's upgrades, downgrades and initiations. I'll be back with some thought on these after I get another cup of my morning fuel (coffee).  Upgrades Sprint by UBS from Neutral to Buy with a $10 price target Res...

Novocure Could Climb Even Further; Here's Where to Buy

Novocure Could Climb Even Further; Here's Where to Buy

The oncology company already has risen significantly this year, but its charts indicate the rally could continue.

NovoCure's Charts Look Bullish

NovoCure's Charts Look Bullish

NovoCure started a strong rally in 2017 and continues to move up.

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Novocure Shares Jump on Phase 3 Data Analysis -- Biotech Movers

Oncology firm released results that show increased compliance with Optune predicted increased survival in patients with glioblastoma, a form of brain cancer.

Rev's Forum: Adapt to a Challenging Market Environment

Rev's Forum: Adapt to a Challenging Market Environment

The normal chart patterns don't operate like they have in the past.

Shark Bites: Focus on the 'Little Picture'

Shark Bites: Focus on the 'Little Picture'

Here's what I'm trading today amid the 'flat with a positive tone' action.

Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman

Bill Doyle's Pershing Exit Adds to Disastrous Quarter for Bill Ackman

Coming off a brutal first quarter, Bill Ackman's hedge fund announced the loss of a key strategist.

NovoCure Debuts on Nasdaq, Despite Weakness in IPO Market

NovoCure Debuts on Nasdaq, Despite Weakness in IPO Market

Cancer treatment company NovoCure (NVCR) debuted as a public company trading on the Nasdaq on Friday, despite weakness seen in the IPO market so far this year.

September Job Growth a Big Disappointment, U.S. Stocks Open Lower

September Job Growth a Big Disappointment, U.S. Stocks Open Lower

U.S. stocks opened lower Friday as the Labor Department stunned Wall Street with a majorly disappointing September jobs report.